Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 1—January 2003

Research

Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Gillian D. Sanders*Comments to Author  and Al V. Taira*
Author affiliations: *Stanford University, Stanford, California, USA

Main Article

Table 2

Intermediate health outcomes of HPV vaccinationa,b

OutcomeHPV vaccinationNo vaccinationLifetime cases avertedNo. needed to vaccinate to prevent one case
HPV
1,460,699
1,684,954
224,255
9
SIL
417,549
530,259
112,710
18
Cervical cancer
13,374
16,690
3,316
600
Cervical-cancer deaths5,1216,4611,3401,484

aAssumes program that successfully administers a vaccine against high-risk HPV to the current U.S. cohort of 12-year-old girls.

bHPV, Human papillomavirus; SIL, squamous intraepithelial lesions.

Main Article

TOP